# Eos

> Eos is a VC fund in Edinburgh backing Biotechnology and Health Care. See 43 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Edinburgh, United Kingdom
- Total investments: 43
- Last investment: Jul 2026
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/eos-advisory
- Website: https://eos-advisory.com/

Eos is a VC fund in Edinburgh focused on Biotechnology and Health Care. Eos Advisory is focused on providing seed funding to ventures based upon strong and innovative science, technology and engineering.

## Contacts

5 contacts available for Eos. Shizune tracks 2 team members at Eos. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/eos-advisory?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.5M–$11M |
| Series A | $1.6M–$47M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 23% |
| Health Care | 5 | 12% |
| Medical | 3 | 7% |
| Therapeutics | 3 | 7% |
| Medical Device | 3 | 7% |

26 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 17 | 40% |
| Funding Round | 6 | 14% |
| Series A | 5 | 12% |
| Series B | 2 | 5% |
| Private Equity | 1 | 2% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 18 | 42% |
| Ireland | 1 | 2% |
| United States | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anne Muir | Director of Portfolio | 1 | https://shizune.co/investors/profile/anne-muir-9063 |
| Kevin Grainger | Founder and Chairman | 2 | https://shizune.co/investors/profile/kevin-grainger |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TaiSan | TaiSan is Battery Materials company, innovated proprietary quasi-solid gel polymer electrolyte and sodium-potassium metal anode to enable quasi-solid-state sodium battery. It leads to best-in-class energy density. We work with battery and automotive OEMs to scale our technology and signed 19 non-binding MoUs. | $6.2M | Seed | Jul 06, 2026 |  |
| Scarlet Therapeutics | Scarlet Therapeutics is developing the novel red blood cell-based therapeutics (tRBCs) generation platform. | $4.4M | Seed | May 07, 2026 |  |
| Bioliberty | Bioliberty are a medtech start-up developing rehabilitation solutions for degenerative and traumatic conditions. | $8.3M | Series A | Mar 18, 2026 |  |
| Neupulse | Neupulse is the brand of Neurotherapeutics LtdThe direction of our current research was very much shaped by the feedback we received from individuals with tic disorders and their families.When we asked them for their thoughts on our research priorities we were frequently told that what was really needed was a safe and effective non-drugtreatment for tic disorder that could be used outside of the clinic and gave individuals control over their tics. This led directly to us focusing on the use of peripheral nerve stimulation as a means of bringing about changes in the brain networks associated with the production of tics. We demonstrated that delivering rhythmic patterns of mild electrical stimulation to the median nerve at the wrist could be used to increase the power and the synchronicity of the brain oscillations (rhythms) associated with the suppression of movements, and that this type of stimulation was sufficient to dramatically reduce the frequency of tics and remove the urge-to-tic in individuals with tic disorders.Importantly, we also showed that this type of stimulation did not materially affect the execution of volitional (intentional) movements or impair cognitive functions such as attention. | $4.1M | Seed | Feb 12, 2026 |  |
| Neupulse | Neupulse is the brand of Neurotherapeutics LtdThe direction of our current research was very much shaped by the feedback we received from individuals with tic disorders and their families.When we asked them for their thoughts on our research priorities we were frequently told that what was really needed was a safe and effective non-drugtreatment for tic disorder that could be used outside of the clinic and gave individuals control over their tics. This led directly to us focusing on the use of peripheral nerve stimulation as a means of bringing about changes in the brain networks associated with the production of tics. We demonstrated that delivering rhythmic patterns of mild electrical stimulation to the median nerve at the wrist could be used to increase the power and the synchronicity of the brain oscillations (rhythms) associated with the suppression of movements, and that this type of stimulation was sufficient to dramatically reduce the frequency of tics and remove the urge-to-tic in individuals with tic disorders.Importantly, we also showed that this type of stimulation did not materially affect the execution of volitional (intentional) movements or impair cognitive functions such as attention. | $4.1M | Seed | Feb 12, 2026 |  |
| Nami Surgical | Nami Surgical provides robotic surgery technology solutions to enhance patient care while giving surgeons intuitive, high-performance moveable instruments. | $2.6M |  | Jan 28, 2026 |  |
| Nami Surgical | Nami Surgical provides robotic surgery technology solutions to enhance patient care while giving surgeons intuitive, high-performance moveable instruments. | $2.6M |  | Jan 28, 2026 |  |
| Chemify | Digitising Chemistry and Chemical Discovery | $50M | Series B | Oct 21, 2025 |  |
| EnsiliTech | EnsiliTech is a biopharmaceuticals company that preserves the integrity of vaccines and other biological materials. | $6.1M | Seed | Aug 28, 2025 |  |
| Laverock Therapeutics | Laverock Therapeutics is a biotechnology company developing programmable gene control technologies for advanced cell and gene therapies. The company builds a platform that uses endogenous microRNA and gene regulatory mechanisms to enable precise, tunable control of gene expression, allowing engineered cells to activate or silence therapeuticfunctions in response to specific biological signals. Its core approach focuses on “disease-responsive” therapies, where engineered cells are designed to sense the surrounding cellular environment and adjust their activity accordingly. This enables therapies that can switch on or off, or modulate activity levels, depending on disease state or tissue context, rather than operating in a constant active mode. The company’s platform supports multiplex gene control, meaning multiple genes can be regulated simultaneously within engineered cells. This capability is applied to developing next-generation cell therapies such as CAR-T cells and macrophages for oncology, as well as exploratory programs in genetic, inflammatory, and metabolic diseases. |  | Seed | Jun 30, 2025 |  |

10 of 43 investments shown.

## Co-investors
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 20 deals together
- [Eos](https://shizune.co/investors/profile/eos-7f20) — VC Fund, 13 deals together
- [Maven Capital Partners](https://shizune.co/investors/profile/maven-capital-partners) — VC Fund, 10 deals together
- [SIS Ventures](https://shizune.co/investors/profile/sis-ventures) — VC Fund, 9 deals together
- [University of Strathclyde](https://shizune.co/investors/profile/university-of-strathclyde) — VC Fund, 7 deals together
- [Old College Capital](https://shizune.co/investors/profile/old-college-capital) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [Chevron Technology Ventures](https://shizune.co/investors/profile/chevron-technology-ventures) — VC Fund
- [Evok Innovations](https://shizune.co/investors/profile/evok-innovations) — VC Fund
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Biotech Investors in United Kingdom](https://shizune.co/investors/biotech-investors-united-kingdom)
- [Biotech VC Funds in United Kingdom](https://shizune.co/investors/biotech-vc-funds-united-kingdom)
- [Biotechnology Investors in Europe](https://shizune.co/investors/biotechnology-investors-europe)
- [Biotechnology VC Funds in Europe](https://shizune.co/investors/biotechnology-vc-funds-europe)
- [Biotech Investors in Europe](https://shizune.co/investors/biotech-investors-europe)
- [Biotech VC Funds in Europe](https://shizune.co/investors/biotech-vc-funds-europe)

## FAQ

### What does Eos invest in?

Eos invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Funding Round stage. Most of the 43 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Eos's check size?

Eos typically joins rounds of $1.5M–$11M at Seed and $1.6M–$47M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eos participates in.

### How do I contact Eos?

Public channels for Eos include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Eos?

The team at Eos includes Anne Muir (Director of Portfolio) and Kevin Grainger (Founder and Chairman). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co